The pharmacological management of severe influenza infection - 'existing and emerging therapies'. (Q30243907)

12 June 2017

1 reference

title

The pharmacological management of severe influenza infection - 'existing and emerging therapies'. (English)

1 reference

12 June 2017

author

Ignacio Martin-Loeches

series ordinal

2

object named as

Ignacio Martin-Loeches

1 reference

12 June 2017

Aisling Mc Mahon

1

1 reference

12 June 2017

language of work or name

English

0 references

publication date

31 October 2016

1 reference

Expert Review of Clinical Pharmacology

12 June 2017

published in

1 reference

12 June 2017

volume

10

1 reference

12 June 2017

issue

1

1 reference

12 June 2017

page(s)

81-95

1 reference

Hospitalization for Influenza A Versus B.

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

21 January 2018

A history of influenza

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Neuraminidase inhibitors for preventing and treating influenza in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Clinical Implications of Antiviral Resistance in Influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

R292K substitution and drug susceptibility of influenza A(H7N9) viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Therapeutic options for the management of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Antivirals for influenza in healthy adults: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Amantadine and rimantadine for influenza A in children and the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Ribavirin's antiviral mechanism of action: lethal mutagenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Use of ribavirin to treat influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Drugs in development for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Arbidol: a broad-spectrum antiviral compound that blocks viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Arbidol for preventing and treating influenza in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

A part-randomized study of intravenous oseltamivir in adolescents and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Influenza virus hemagglutinin stalk-based antibodies and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Statins for the prevention and treatment of infections: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Increased survival after gemfibrozil treatment of severe mouse influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Chinese medicinal herbs for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Bacterial coinfection in influenza: a grand rounds review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Increased incidence of co-infection in critically ill patients with influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Estimating influenza-associated deaths in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

The Ongoing Battle Against Influenza: Drug-resistant influenza viruses: why fitness matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Influenza-Associated Pediatric Mortality in the United States: Increase of Staphylococcus aureus Coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

The burden of influenza B: a structured literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1255550

10.1080/17512433.2017.1255550

21 January 2018

Identifiers

DOI

1 reference

release_itodkegr4ve5ncpqboqvlx6sza

12 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/itodkegr4ve5ncpqboqvlx6sza

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference